Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

P VIII 101

Next Previous
Drug Profile

P VIII 101

Alternative Names: P-FVIII-101; P-VIII-101

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Poseida Therapeutics
  • Class Antihaemorrhagics; Gene therapies
  • Mechanism of Action Factor VIII replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Haemophilia A

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for preclinical development in Haemophilia-A in USA (IV, Injection)
  • 07 Nov 2024 Poseida had a successful INTERACT meeting with the US FDA for P FVIII 101
  • 05 Aug 2024 The US FDA grants an INTERACT Meeting to P VIII 101 for Hemophilia A in September 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top